NASDAQHealth CareBiotechnologySnapshot 2026-07-23
Reading HRMY? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment is characterized as a durable compounder with a stable management team and robust earnings quality. The current thesis state remains intact, despite recent challenges and a muted price reaction.
The valuation is considered cheap compared to peers, with a notable expectations gap. The market seems to have priced in some level of fragility, but there are no immediate signs of instability.
Fundamentals are likely to remain strong, supported by management's commitment to achieving revenue targets and advancing their product pipeline. However, there is an elevated risk of a near-term earnings miss, as the company has recently experienced consecutive misses.
The long-term thesis hinges on the performance of sector bellwethers and the company's ability to maintain guidance. Positive momentum in the healthcare sector could support HRMY, while any negative shifts from industry leaders could pose risks.
Overall, HRMY has a solid foundation but faces challenges that could impact its trajectory in the near term. Not investment advice.
The most important moves since the prior daily snapshot.
Valuation rose by 17.4 points (from 66.5 to 83.9).
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Revenue growth is key for Harmony. A drop below 10% signals trouble in the sector.
Confirms:Q2 revenue growth reported below 10% year over year.
Disproves:Q2 revenue growth stays at or above 10% year over year.
Why it matters: The Q2 results will show if Harmony can maintain its revenue growth trend. Investors will look for confirmation of the $1.0 billion to $1.04 billion guidance.
Confirms:Q2 2026 net product revenue reported above $261 million, continuing the growth trend.
Disproves:Q2 2026 net product revenue was below $261 million. This shows a slowdown.
Why it matters: The result could affect WAKIX's market position. It may also change revenue from pitolisant.
Confirms:The lawsuit against AET Pharma/Sandoz ends with a good ruling for Harmony.
Disproves:The lawsuit ends with a ruling against Harmony. This affects its IP strategy.
Why it matters: The new CFO could change financial strategy. This may affect efficiency and growth.
Confirms one read:The next quarterly report may show more operating income. This comes after the CFO change.
Confirms the other:A drop in operating income is expected in the next quarterly report.
Why it matters: Good data could improve the product's market position and increase its use, raising revenue.
Confirms:A press release shares good news from the Phase 3 study for Pitolisant. This study is for Prader-Willi syndrome.
Disproves:Negative or unclear results came from the Phase 3 study for Pitolisant in PWS.
Why it matters: Better operating income is important. It shows the company is managing costs well.
Confirms:Operating income goes up each quarter.
Disproves:Operating income goes down or stays the same each quarter.
Why it matters: This filing is key for expanding the Pitolisant franchise and could drive future revenue.
Confirms:An announcement confirms the NDA filing for Pitolisant GR in Q2 2026.
Disproves:No announcement or delay in the NDA filing for Pitolisant GR.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Why it matters: Good results could support Harmony's pipeline plan. This may boost growth in new markets.
Confirms:Positive data from the Phase 1 study of BP-205 reported in mid-2026.
Disproves:Negative data or delays in reporting Phase 1 study results for BP-205.
Why it matters: The success of the kids' indication will affect total sales and help meet revenue goals.
Confirms:Sales grew a lot in the kids' area after FDA approval on February 13.
Disproves:Sales growth is slow. There are market access problems for the kids' area after approval.
Why it matters: The CFO change may affect financial plans and actions. Strong leadership helps keep investor trust.
Confirms:The new CFO, Stephen Mollichella, runs financial operations well. There are no issues.
Disproves:More changes in leadership or problems in the finance team could disrupt operations or guidance.
